TRIM24 and cancer: The significant association between anti-TIF1 autoantibodies and cancer (ever) only existed for patients ≥50 years of age vs patients <50 years of age; OR 3.62 (95% CI 2.09–6.28, p < 0.0001) and OR 1.97 (95% CI 0.56–6.99, p = 0.2940), respectively.